Pharmaceutical intelligence platform spanning drug development lifecycle
Norstella operates a portfolio of five pharmaceutical solutions brands—Citeline, Evaluate, MMIT, Panalgo, The Dedham Group—serving the drug development value chain. The tech stack reveals a data-heavy organization: Snowflake + SQL + dbt foundations, analytics via Tableau and Power BI, LLM inference (Llama 3, Mixtral, Gemma) for unstructured medical-data extraction, and infrastructure automation (Terraform, Kubernetes, AWS Lambda). Hiring is heavily weighted toward data (22 roles) and engineering (16), with senior-level concentration—a pattern typical of organizations scaling real-world data pipelines and automation in regulated, data-dense domains.
Norstella is a group of pharmaceutical intelligence and consulting businesses operating across clinical-trial design, regulatory strategy, market access, medical-data management, and real-world evidence (RWE) for life sciences companies. The portfolio serves sponsors, CROs, and payers navigating drug development from pipeline strategy through patient access. Operating at 1,001–5,000 employees across the United States, India, and United Kingdom, the organization is currently focused on scaling real-world datasets, automating quality controls, and extracting value from unstructured clinical and medical records. Key operational challenges include managing legacy workflows, cleansing and deduplicating heterogeneous data sources, and accelerating the adoption of real-world evidence in development decisions.
Snowflake, SQL, Tableau, Power BI, React, Node.js, AWS (Lambda, Kubernetes, CloudFormation), Salesforce, NetSuite, Llama 3, Mixtral, Gemma for ML, and monitoring via Prometheus, Grafana, New Relic.
Real-world evidence platforms, quality-control automation, multimodal medical datasets for drug development, reimbursement strategy tools, knowledge-base management, and field-team enablement for new RWE products.
Other companies in the same industry, closest in size